癌变·畸变·突变 ›› 2021, Vol. 33 ›› Issue (6): 426-429,434.doi: 10.3969/j.issn.1004-616x.2021.06.004

• 论著 • 上一篇    下一篇

氧化苦参碱对小鼠肉瘤和肝癌的体内外抗肿瘤作用

刘宁1, 梁兰兰1, 李淑芳1, 沈祥春1,2, 梁冰1   

  1. 1. 贵州医科大学基础医学院药理学教研室, 贵州 贵阳 550025;
    2. 贵州医科大学天然药物优效利用重点实验室, 贵州 贵阳 550025
  • 收稿日期:2021-05-27 修回日期:2021-10-12 出版日期:2021-11-30 发布日期:2021-12-04
  • 通讯作者: 沈祥春,E-mail:shenxiangchun@126.com;梁冰,E-mail:bliang163@163.com E-mail:shenxiangchun@126.com;bliang163@163.com
  • 作者简介:刘宁,E-mail:1193982972@qq.com。
  • 基金资助:
    贵州省高层次创新型人才百层次人才项目([2015]4029);贵州省高层次创新型人才千层次人才项目

Anti-tumor effects of oxymatrine on mouse sarcoma and live cancers in vivo and in vitro

LIU Ning1, LIANG Lanlan1, LI Shufang1, SHEN Xiangchun1,2, LIANG Bing1   

  1. 1. Department of Pharmacology, School of Basic Medical Sciences, Guizhou Medical University, Guiyang 550025;
    2. The Key Laboratory of Optimal Utilization of Natural Medicine Resources, Guizhou Medical University, Guiyang 550025, Guizhou, China
  • Received:2021-05-27 Revised:2021-10-12 Online:2021-11-30 Published:2021-12-04

摘要: 目的: 研究氧化苦参碱对小鼠肉瘤和肝癌的体内、外抗肿瘤作用,为氧化苦参碱在抗肿瘤方面的应用提供实验依据。方法: 取对数生长期S180和H22细胞悬液预培养24 h,分别设立小鼠S180和H22细胞的空白对照组(RPMI-1640培养基)、阴性对照组(不加药的S180和H22细胞悬液)、5-氟尿嘧啶(5-FU,5×10-5 g/L)阳性对照组及5个不同浓度(1×10-4、1×10-5、1×10-6、1×10-7、1×10-8 g/L)的氧化苦参碱培养组,连续培养48 h后,采用四甲基噻唑蓝(MTT)法检测氧化苦参碱对S180和H22细胞的增殖抑制率。分别将S180和H22瘤细胞悬液接种于昆明种小鼠,建立S180和H22荷瘤小鼠模型,分别设立正常对照组、模型组、阳性对照组、氧化苦参碱高、中、低剂量组,每组10只。正常对照组和模型组灌胃给予等体积蒸馏水,高、中、低剂量小鼠分别灌胃浓度为100、50、25 mg/kg的氧化苦参碱,阳性对照组灌胃给予30 mg/kg的环磷酰胺。各组连续给药8 d后,检测氧化苦参碱对S180和H22荷瘤小鼠的抑瘤率、胸腺系数和脾系数以及对S180和H22腹水瘤小鼠生存期的影响。结果: 体外研究结果表明,与阴性对照组比较,氧化苦参碱对小鼠S180和H22细胞的增殖均有抑制作用(P<0.05)。动物实验表明,与模型组比较,氧化苦参碱100、50和25 mg/kg剂量组均能够显著抑制小鼠S180肉瘤的生长,抑瘤率分别为48.48%、41.67%和32.58%,差异具有统计学意义(P<0.05);氧化苦参碱100和50 mg/kg剂量组均能够显著抑制小鼠肝癌H22的生长,抑瘤率分别为33.95%和31.63%,差异具有统计学意义(P<0.05);氧化苦参碱50 mg/kg剂量组可显著延长S180腹水型小鼠的生存期,其生命延长率为31.18%,差异具有统计学意义(P<0.05)。与正常对照组比较,氧化苦参碱各剂量组对S180荷瘤小鼠和H22荷瘤小鼠的胸腺系数和脾系数无明显影响(P>0.05)。结论: 氧化苦参碱对小鼠肉瘤和肝癌体外和体内均具有一定的抗肿瘤作用。

关键词: 氧化苦参碱, 抗肿瘤, S180, H22, 小鼠

Abstract: OBJECTIVE: To investigate anti-tumor effects of oxymatrine on S180 and H22 tumor bearing mice in vivo and in vitro,and to provide experimental basis for application of oxymatrine in treatment of cancers. METHODS: In vitro cell culture:S180 and H22 cell suspensions at logarithmic growth stage were precultured for 24 h. Mice S180 and H22 cells were divided into blank control group (RPMI-1640 medium),negative control group (un-supplemented S180 and H22 cell suspension),5-fluorouracil (5-FU,5×10-5 g/L) positive control group and 5 different concentrations of oxymatrine (1×10-4,1×10-5,1×10-6,1×10-7,1×10-8 g/L). After 48 h of continuous culture,proliferation inhibition rates of oxymatrine on S180 and H22 cells were detected by tetramethylthiazolyl blue (MTT) method. In vitro animal experiments using our S180 and H22 tumor-bearing mouse models were:normal control group,model group,positive control group,and oxymatrine high-dose,medium-dose and low-dose groups were set up respectively,with 10 mice in each group. Normal control group and model group were intra-gastrically fed with distilled water,high,medium and low dose mice were intra-gastrically fed with oxymatrine at different concentrations (100,50 and 25 mg/kg),and positive control group was intra-gastrically fed with cyclophosphamide at 30 mg/kg. After 8 days of continuous administration,the inhibitory rate,thymus coefficient and spleen coefficient of oxymatrine on S180 and H22 tumor bearing mice and the survival of S180 and H22 ascites tumor mice were detected. RESULTS: Our results showed that oxymatrine inhibited proliferation of S180 and H22 cells in vitro as detected with the MTT method. Results from our in vivo studies showed that oxymatrine high,medium and low dose group significantly inhibited growth of S180 sarcoma in mice,and the tumor inhibition rate were 48.48%,41.67% and 32.58% respectively;oxymatrine high and medium dose group significantly inhibited the growth of H22 sarcoma in mice,and the tumor inhibition rate were 33.95%,31.63% respectively,and the difference was statistically significant. Oxymatrine medium dose group significantly prolonged the survival time of S180 mice. The life extension rate was 31.18%,and the difference was statistically significant. Compared with the normal group,each dose group of oxymatrine had no effect on the thymus index and spleen index in S180 and H22 mice. CONCLUSION: Oxymatrine demonstrated anti-tumor effects on S180 and H22 in vitro and in vivo.

Key words: oxymatrine, anti-tumor effect, S180, H22, mouse

中图分类号: